The utility of the [-2]pro-prostate-specific antigen level as a prognostic marker in patients with castration-resistant prostate cancer treated with enzalutamide.

Yoshiyuki MiyazawaKeisuke HoriYusuke TsujiYoshitaka SekineSeiji AraiYuji FujizukaMasashi NomuraHidekazu KoikeHiroshi MatsuiKazuhiro Suzuki

Published in: International journal of urology : official journal of the Japanese Urological Association (2023)

Our study elucidates the usefulness of p2PSA in predicting outcomes for CRPC patients treated with enzalutamide. It suggests that p2PSA and phi may be prognostic markers after enzalutamide administration in CRPC patients.

Keyphrases

prostate cancer
radical prostatectomy
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
adipose tissue
skeletal muscle